I think this cooperation between Quagen and Neuron23 implies that introduction of biomarker and CDx is expanding to various therapeutic areas beyond oncology. - Onco was study area where all the innovative CDx and personalized treatment were firstly introduced, but now we’re seeing the change in other therapeutic areas. The CEO of Neuron23 achieved big investment from Softbank Vision Fund bases ..